AstraZeneca’s Tagrisso shows promise in combating advanced lung cancer

Giles Coghlan LLB, Lth, MA Financial Source

Lung cancer is a major global health concern and ranks as the deadliest type of cancer, accounting for approximately one in five cancer-related deaths, according to the World Health Organization. In 2020 alone, there were approximately 2.2 million new diagnoses of lung cancer. Therefore, the news about AstraZeneca’s new drug Tagrisso could be great for the global fight against cancer and AstraZeneca’s outlook.

Tagrisso has been reported on by Bloomberg to demonstrate its ability to delay the progression of advanced lung cancer when combined with chemotherapy. This would mark a significant advancement in the treatment of this deadly disease. The study’s findings indicate that the combination of Tagrisso and chemotherapy extended the time before the worsening of advanced non-small cell lung tumors by an impressive nine months compared to Tagrisso alone. Additionally, this combination therapy reduced the risk of death or disease progression by 38% when compared to Tagrisso used as a single therapy.

These results are expected to set a new standard for delaying the progression of the disease, according to Susan Galbraith, Executive Vice President of Oncology Research and Development at AstraZeneca. Tagrisso is already the UK-based pharmaceutical company’s best-selling drug, generating $5.4 billion in revenue and contributing significantly to the company’s 2022 earnings.

David Fredrickson, Executive Vice President of Oncology at AstraZeneca, emphasized the importance of advancing treatment options beyond monotherapy, highlighting Tagrisso as the cornerstone of lung cancer treatment for patients with a specific genetic mutation known as EGFR.
According to the study, patients receiving the combination therapy experienced a median survival time of 25.5 months (by investigator assessment) and 29.4 months (by blinded independent central review) before the cancer progressed. In contrast, those who received Tagrisso alone had median survival times of 16.7 months and 19.9 months, respectively. Although overall survival data is still preliminary, the results favour Tagrisso combined with chemotherapy.

Despite this positive development, analysts from Bloomberg Intelligence, John Murphy and Sam Fazeli, noted that the study’s results present a mixed message and create a competitive landscape for rival pharmaceutical companies like Johnson & Johnson. They highlighted the significant success of AstraZeneca in achieving the primary endpoint of the trial but expressed concern about the absence of a clear trend favouring an overall survival benefit. So, to the extent this significant progress impacts AstraZeneca’s share price still remains to be seen.

Learn more about HYCM

Author

Giles Coghlan LLB, Lth, MA

Financial Source

Giles is the chief market analyst for Financial Source. His goal is to help you find simple, high-conviction fundamental trade opportunities. He has regular media presentations being featured in National and International Press.

AUD/USD eyes 0.7150 barrier nine-day EMA

AUD/USD inches higher after registering modest losses in the previous day, trading around 0.7130 during the Asian hours. The technical analysis of the daily chart indicates that the pair is moving sideways within the rectangle pattern, suggesting a consolidation as neither the bulls nor the bears have enough momentum to take control of the market.

USD/JPY trades below 160.00 intervention threshold; bullish bias intact

The USD/JPY pair attracts some sellers during the Asian session amid fears that authorities will step in again to prop up the Japanese Yen. Furthermore, the Israel-Lebanon truce prompts some profit-taking around the US Dollar and exerts downward pressure on the currency pair.

Gold puts its 200-day SMA to the test near $4,420

Gold keeps the bullish stance in place in the latter part of Thursday’s session, although a convincing break above the key $4,500 mark per troy ounce still remains elusive. The precious metal’s advance comes amid the resurgence of some selling interest around the Greenback, improving risk sentiment, and declining US Treasury yields across the board.

Bitcoin’s massive storm is back: Why the sell-off is far from over

Bitcoin price action over the last few weeks has felt less like a normal, healthy correction and more like a slow grinding crash that continues to wreak havoc on holdings and trading accounts. And everything suggests that the dramatic crash isn’t over.

Nonfarm payrolls: Testing the limits of Fed policy patience

The upcoming nonfarm payrolls report for May will provide the final update on the US labor market before Kevin Warsh attends his first policy meeting as the new Fed Chair later this month.

Recession on paper: What really moves the Canadian Loonie now?

Statistics Canada handed the headline writers a gift and the analysts a headache. Real GDP shrank 0.1% on an annualized basis in the first quarter, and with the fourth quarter of 2025 revised down to a 1.0% contraction, that is two negative quarters in a row, the textbook definition of a technical recession and Canada's first since the pandemic.